Product Description
TNX-2900 is based on Tonix's patented intranasal potentiated oxytocin formulation. Tonix is also developing a different intranasal formulation and device, designated TNX-1900, for prophylaxis of chronic migraine and for the treatment of insulin resistance and related conditions. (Sourced from: https://www.tonixpharma.com/news-events/press-releases/detail/1250/tonix-pharmaceuticals-licenses-technology-for-treating)
Mechanisms of Action: OXTR Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: Orphan Drug - Prader-Willi Syndrome *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tonix Pharmaceuticals
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Trial Start Expected - Tonix Pharmaceuticals announced they will initiate a P2 Prader-Willi Syndrome trial in 2H26 for TNX-2900
- Clinical Outcomes Reported - Tonix Pharmaceuticals presented P2 Prader-Willi Syndrome results on 2024-03-21 for TNX-2900
Highest Development Phases
Phase 0: Prader-Willi Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|